List of Excipients in Branded Drug BRIMONIDINE TARTRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	BORIC ACID
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	CALCIUM CHLORIDE
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	HYDROCHLORIC ACID
Physicians Total Care Inc	BRIMONIDINE TARTRATE	brimonidine tartrate	54868-6094	MAGNESIUM CHLORIDE

Generic Drugs Containing BRIMONIDINE TARTRATE

Company	Ingredient	NDC	Excipient
Walgreens Company	brimonidine tartrate	0363-9960	BENZALKONIUM CHLORIDE
Walgreens Company	brimonidine tartrate	0363-9960	BORIC ACID
Walgreens Company	brimonidine tartrate	0363-9960	CALCIUM CHLORIDE
Walgreens Company	brimonidine tartrate	0363-9960	GLYCERIN

What are the Most Frequently-Used Excipients in BRIMONIDINE TARTRATE?

# Of NDCs	Excipient
13	BENZALKONIUM CHLORIDE
7	BORIC ACID
7	CALCIUM CHLORIDE
1	CARBOXYMETHYLCELLULOSE

Excipient Strategy and Commercial Opportunities for Brimonidine Tartrate

Last updated: February 28, 2026

What are the key excipient considerations for Brimonidine Tartrate formulations?

Brimonidine tartrate is primarily used as a topical ophthalmic solution and a topical gel for the treatment of glaucoma and ocular hypertension. The formulation's efficacy, stability, and patient tolerability hinge on the selection of appropriate excipients.

Common excipients in Brimonidine Tartrate products

• Preservatives: Benzalkonium chloride (BAK) is widely used for its antimicrobial activity, though preservative-free formulations are gaining prominence.
• Viscosity agents: Hydroxypropyl methylcellulose (HPMC) and carboxymethylcellulose improve ocular residence time.
• Buffers: Phosphate buffers stabilize pH around 6.0-6.5 to enhance stability and comfort.
• Isotonic agents: Sodium chloride maintains isotonicity with tear fluid.
• Solvents: Purified water serves as solvent, with stabilizing agents preventing degradation.

Challenges in excipient design

• Ensuring compatibility with the active pharmaceutical ingredient (API) to prevent degradation.
• Minimizing ocular irritation, especially with preservatives.
• Extending shelf life through stabilization of excipient-API interactions.

How does excipient choice impact the commercial landscape?

Patient compliance and market differentiation

• Preservative-free formulations appeal to sensitive patient populations and can command premium pricing.
• Ocular comfort through optimized viscosity agents and buffers enhances adherence, supporting brand loyalty.

Regulatory trend influences

• Increased regulatory scrutiny over preservatives pushes manufacturers toward preservative-free delivery systems.
• Development of single-dose, preservative-free vials provides a competitive edge.

Production considerations

• Compatibility with large-scale manufacturing processes affects cost-efficiency.
• Stability profiles influence shelf life and distribution logistics.

Intellectual property implications

• Novel excipient combinations or delivery systems can support patent filings, extending product lifecycle.

What are emerging commercial opportunities related to excipient strategies?

Innovation in preservative-free systems

• Multi-dose devices with preservative-free formulations (e.g., unidirectional valves) reduce preservative-related concerns.

New excipient technologies

• Use of biocompatible, mucoadhesive polymers to enhance residence time, possibly reducing dosing frequency.
• Utilization of lyophilized formulations combined with innovative reconstitution systems to improve stability and patient convenience.

Reformulation for differential benefits

• Transitioning from solution to gel formulations to improve ocular retention.
• Incorporating anti-inflammatory excipients to provide combined therapeutic effects.

Market expansion

• Preservative-free options positioned for global markets, especially in regions with stringent regulations.
• Developing formulations tailored for specific populations, e.g., pediatric, elderly, or contact lens wearers.

What are the key patent landscapes and market considerations?

Aspect	Details
Patent drafting	Focuses on unique excipient combinations, drug delivery devices, or novel stabilization methods.
Market size	Expected CAGR of 6.7% (2021-2028), driven by rising glaucoma prevalence.
Competitive dynamics	Major players include Allergan, Santen, and Akorn, investing in preservative-free innovations.

Regulatory environment

• The U.S. FDA favors preservative-free, multidose systems.
• EMA encourages preservative-free ophthalmic products due to safety profiles.

Summary of excipient and market insights

Aspect	Details
Excipient considerations	Stabilize API, ensure ocular tolerance, facilitate manufacturing.
Commercial opportunities	Preservative-free formulations, innovative delivery systems, targeted market segments.
Regulatory trends	Shift toward preservative-free, patient-centric solutions.
Market dynamics	Growth driven by aging populations, glaucoma prevalence, and regulatory changes.

Key Takeaways

• Excipient selection critically influences the stability, tolerability, and marketability of Brimonidine Tartrate products.
• Preservative-free formulations and advanced delivery systems present lucrative opportunities.
• Regulatory shifts favor innovations that improve safety and compliance.
• Patent strategies focus on novel excipient combinations and device innovations.
• Growth hinges on expanding patient-specific formulations and penetrating emerging markets.

FAQs

1. What are the main challenges in formulating Brimonidine Tartrate?
Stability issues related to API degradation and ocular irritation caused by preservatives.

2. How do preservative-free formulations benefit patients?
They reduce ocular irritation risks and are suitable for sensitive or long-term users.

3. Which excipients are most commonly used in Brimonidine Tartrate eye drops?
Buffers (phosphate), viscosity agents (HPMC), preservatives (BAK), isotonic agents (sodium chloride).

4. What emerging excipient technologies could improve Brimonidine formulations?
Mucoadhesive polymers for longer residence time and lyophilized systems for improved stability.

5. How does the market for Brimonidine Tartrate products look?
It is growing steadily, driven by glaucoma prevalence and regulatory push for preservative-free solutions.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Ophthalmic drugs—regulatory considerations.
[2] MarketsandMarkets. (2022). Ophthalmic drugs market by Type, Application, and Geography.
[3] Singh, P., et al. (2020). Advances in ophthalmic drug delivery systems. Journal of Pharmaceutics, 2020.